Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
Mayo Clinic
National Cancer Institute, Egypt
H. Lee Moffitt Cancer Center and Research Institute
Immatics US, Inc.
HRYZ Biotech Co.
Brooklyn ImmunoTherapeutics, LLC
Fate Therapeutics
CEL-SCI Corporation
Genocea Biosciences, Inc.
Gliknik Inc.
Brooklyn ImmunoTherapeutics, LLC
Masonic Cancer Center, University of Minnesota
Emory University
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins